Intestinal elimination of ofloxacin enantiomers in the rat: Evidence of a carrier-mediated process

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 9, 1996, Pages 2126-2130

  Rabbaa, Lydia ^a   Dautrey, Sophie ^b   Colas Linhart, Nicole ^b   Carbon, Claude ^b   Farinotti, Robert ^a,b  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CEFOPERAZONE; CIPROFLOXACIN; DRUG CARRIER; GLYCOPROTEIN P; OFLOXACIN; PEFLOXACIN; QUINIDINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VERAPAMIL;

ANIMAL EXPERIMENT; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; CAROTID ARTERY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG TRANSPORT; ENANTIOMER; INTESTINE ABSORPTION; INTESTINE FLORA; INTRAARTERIAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STEREOCHEMISTRY;

EID: 0029823966     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.9.2126     Document Type: Article

References (40)

1. 3H]CGP-12177 and its use to determine the rate constants of unlabeled β-adrenergic antagonists. Proc. Natl. Acad. Sci. USA 82:925-929.
2. Allen, C. N., E. S. Harpur, T. J. B. Gray, N. L. Simmons, and B. H. Hirst. 1990. Efflux of bis-carboxyethyl-carboxyfluorescein (BCECF) by a novel ATP-dependent transport mechanism in epithelial cells. Biochem. Biophys. Res. Commun. 172:262-267.
3. Beermann, D., H. Scholl, W. Wingender, D. Forster, E. Beutler, and W. R. Kukovetz. 1986. Metabolism of ciprofloxacin in man, p. 141-149. In H. C. Neu and H. Weuta (ed.), Proceedings of the 1st International Ciprofloxacin Workshop. Excerpta Medica, Amsterdam.
4. Bressolle, F., F. Gonçalves, A. Gouby, and M. Galtier. 1994. Pefloxacin clinical pharmacokinetics. Clin. Pharmacokinet. 27:418-446.
5. Croop, J. M., M. Raymond, D. Haber, A. Devault, R. J. Arceci, P. Gros, and D. E. Houseman. 1989. The three multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal human tissues. Mol. Cell. Biol. 9:1346-1350.
6. Fass, R. J. 1985. Quinolones. Ann. Intern. Med. 102:400-401.
7. Ford, J., and W. N. Hait. 1990. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev. 42:155-199.
8. Freeman, C. D., D. P. Nicolau, P. P. Belliveau, and C. H. Nightingale. 1993. Lomefloxacin clinical pharmacokinetics. Clin. Pharmacokinet. 25:6-19.
9. Fujimoto, T., and S. Mitsuhashi. 1990. In vitro antibacterial activity of DR-3355, the S-(-)-isomer of ofloxacin. Chemotherapy 36:268-276.
10. Furet, Y. X., J. Deshusses, and J.-C. Pechère. 1992. Transport of pefloxacin across the bacterial cytoplasmic membrane in quinolone-susceptible Staphylococcus aureus. Antimicrob. Agents Chemother. 36:2506-2511.
11. Gasic, S., H. G. Eichler, and A. Korn. 1987. Comparative effects of verapamil, tiapamil, diltiazem and nifedipine on systemic and splanchnic hemodynamics in man. Int. J. Clin. Pharmacol. Ther. Tox. 25:498-503.
12. Granneman, G. R., U. Stephan, B. Borner, F. Sörgel, and D. Mukherjee. 1992. Effect of antacid medication on the pharmacokinetics of temafloxacin. Clin. Pharmacokinet. 22:83-89.
13. Griffith, N. M., B. H. Hirst, and N. L. Simmons. 1993. Active secretion of the fluoroquinolone ciprofloxacin by human intestinal epithelial Caco-2 cell layers. Br. J. Pharmacol. 108:575-576.
14. Griffith, N. M., B. H. Hirst, and N. L. Simmons. 1994. Active intestinal secretion of the fluoroquinolone antibacterials ciprofloxacin, norfloxacin and pefloxacin: a common secretory pathway? J. Pharmacol. Exp. Ther. 269:496-502.
15. Gruber, G., U. Jaehde, and F. Sörgel. 1988. Relationships between the chemical structure and the HPLC capacity factor of gyrase inhibitors and their metabolites in different methanol-water eluents. Fresenius Z. Anal. Chem. 330:388-389.
16. Hirai, K., H. Aoyama, T. Irikura, S. Iyobe, and S. Mitsuhashi. 1986. Differences in susceptibility to quinolones of outer membrane mutants of Salmonella typhimurium and Escherichia coli. Antimicrob. Agents Chemother. 29: 535-538.
17. Hirano, T., K. Iseki, S. Miyazaki, M. Takada, M. Kobayashi, M. Sugawara, and K. Miyazaki. 1994. The stimulative effect of diffusion potential on enoxacin uptake across rat intestinal brush-border membranes. J. Pharm. Pharmacol. 46:676-679.
18. Hoiby, N. 1986. Clinical uses of nalidixic acid analogues: the fluoroquinolones. Eur. J. Clin. Microbiol. 5:138-140.
19. Hooper, D. C., and J. S. Wolfson. 1988. Mode of action of the quinolones antimicrobial agents. Rev. Infect. Dis. 10:14-21.
20. Huneau, J. F., D. Tome, J. Ramon, C. Carbon, and E. Rubinstein. 1993. Absorption and secretion of sparfloxacin in the isolated rabbit intestinal tract. Drugs 45:251.
21. Ince, P., K. Elliott, D. R. Appleton, M. Moorghen, K. J. Finney, J. P. Sunter, A. L. Harris, and A. J. Watson. 1991. Modulation by verapamil of vincristine pharmacokinetics and sensitivity to metaphase arrest of the normal rat colon in organ culture. Biochem. Pharmacol. 41:1217-1225.
22. Le Coguic, A., R. Bidault, R. Farinotti, and A. Dauphin. 1988. Determination of ofloxacin in plasma and urine by liquid chromatography. J. Chromatogr. 434:320-323.
23. Lode, H., G. Höffken, P. Olschewski, B. Sievers, A. Kirch, K. Borner, and P. Koeppe. 1987. Pharmacokinetics of ofloxacin after parenteral and oral administration. Antimicrob. Agents Chemother. 31:1338-1342.
24. Lode, H., G. Höffken, C. Prinzing, P. Glatzel, K. Wiley, P. Olschewski, B. Sievers, D. Reimnitz, K. Borner, and P. Koeppe. 1987. Comparative pharmacokinetics of new quinolones. Drugs 34:21-25.
25. Okazaki, O., C. Kojima, H. Hakusui, and M. Nakashima. 1991. Enantioselective disposition of ofloxacin in humans. Antimicrob. Agents Chemother. 35:2106-2109.
26. Okazaki, O., T. Kurata, and H. Tachizawa. 1989. Stereoselective metabolic disposition of enantiomers of ofloxacin in rats. Xenobiotica 19:419-429.
27. Rubinstein, E., S. Dautrey, R. Farinotti, L. St. Julien, J. Ramon, and C. Carbon. 1995. Intestinal elimination of sparfloxacin, fleroxacin, and ciprofloxacin in rats. Antimicrob. Agents Chemother. 39:99-102.
28. Rubinstein, E., L. St. Julien, J. Ramon, S. Dautrey, R. Farinotti, J.-F. Huneau, and C. Carbon. 1994. The intestinal elimination of ciprofloxacin in the rat. J. Infect. Dis. 169:218-221.
29. Savina, P. M., A. E. Staubus, T. S. Gaginella, and D. F. Smith. 1981. Optimal perfusion rate determined for in situ intestinal absorption studies in rats. J. Pharm. Sci. 70:239-243.
30. Segeti, J., L. J. Goodman, R. M. Petrak, R. L. Kaplan, G. W. Parkhurst, and G. M. Trenholme. 1988. Serum and faecal levels of ciprofloxacin and trimethoprim-sulfamethoxazole in adults with diarrhea. Rev. Infect. Dis. 10(Suppl. 1):S206-S207.
31. Shanker, L. S., D. J. Tocco, B. B. Brodie, and C. A. Hogben. 1958. Absorption of drugs from the rat small intestine. J. Pharmacol. Exp. Ther. 123:81-88.
32. Sharma, R. C., S. Inoue, J. Roitelman, R. T. Schimke, and R. D. Simoni. 1992. Peptide transport by the multidrug resistance pump. J. Biol. Chem. 267:5731-5734.
33. Shimada, J., T. Yamaji, Y. Ueda, H. Uchida, H. Kusajima, and T. Urikura. 1983. Mechanism of renal excretion of AM-715, a new quinolonecarboxylic acid derivative, in rabbits, dogs, and humans. Antimicrob. Agents Chemother. 23:1-7.
34. Sörgel, F., and M. Kinzing. 1993. Pharmacokinetics of gyrase inhibitors, part 1: basic chemistry and gastrointestinal disposition. Am. J. Med. 94:3A-44S.
35. Sörgel, F., K. G. Naber, U. Jaehde, G. Mahr, P. Muth, and A. Reiter. 1991. Die gastrointestinale Sekretion von Antibiotika am Beispeil von Ciprofloxacin, p. 319-326. In D. Adam, T. Bergan, and G. Ruckdeschel (ed.), Paul-Ehrlich-Gesellschaft. Fortscritte des antimikrobiellen und antineoplastischen Chemotherapie. Futuramed, Munich.
36. Sörgel, F., K. G. Naber, U. Jaehde, A. Reiner, R. Seelmann, and G. Sigl. 1989. Gastrointestinal secretion of ciprofloxacin. Am. J. Med. 87:62S-65S.
37. Thiebaut, F., T. Tsuruo, H. Hamada, M. M. Gottesman, I. Pastan, and M. C. Willingham. 1987. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA 84:7735-7738.
38. Vergin, H., R. Metz, R. Nau, M. Kinzing, and F. Sörgel. 1993. Elimination of lomefloxacin in rat intestinal loop. Drugs 45:252.
39. Weiland, G. A., and R. E. Oswald. 1985. The mechanism of binding of dihydropyridine calcium channel blockers to rat brain membranes. J. Biol. Chem. 260:8456-8464.
40. Wolfson, J., and D. C. Hooper. 1991. Pharmacokinetics of quinolones: newer aspects. Eur. J. Clin. Microbiol. Infect. Dis. 10(Special issue):47-54.